DEA Issues Official Correction for Bromazolam Spelling Error
Published Date: 6/24/2026
Rule
Summary
The DEA fixed a typo in the official chemical name of bromazolam, a drug they put in the strictest Schedule I category starting March 16, 2026. This correction makes the rules clear for everyone involved, especially law enforcement and drug handlers. No new fees or deadlines, just a clean-up to keep things accurate and official.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Bromazolam placed in Schedule I
On March 16, 2026, the Drug Enforcement Administration placed bromazolam in Schedule I, the strictest category under the Controlled Substances Act. A correcting amendment effective June 24, 2026 fixes the official chemical name (8-bromo-1-methyl-6-phenyl-4H-benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine) to make the rule clear for law enforcement and drug handlers.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-19538, Bulk Manufacturer of Controlled Substances Application: Cambridge Isotope Laboratories, Inc.
Cambridge Isotope Laboratories wants to make a lot of a special drug called Tetrahydrocannabinols for testing purposes. People who already make or use this drug can share their thoughts by December 23, 2026, and ask for a hearing by November 23, 2026. This move could help scientists get better testing materials without changing how the drug is used.
2026-19540, Importer of Controlled Substances Application: Fisher Clinical Services, Inc. (I)
Fisher Clinical Services, Inc. wants to become an official importer of certain controlled substances like marijuana and its extracts. This affects companies involved in drug manufacturing and importation, who can comment or request a hearing by October 26, 2026. No direct costs are mentioned, but this move could impact how these substances enter the U.S. market.
2026-19542, Bulk Manufacturer of Controlled Substances Application: Cayman Chemical Company
Cayman Chemical Company wants to become an official bulk maker of some powerful controlled substances, mostly in Schedule I. This means they’ll be able to produce these drugs in large amounts for research or medical use. If you have thoughts or objections, you’ve got until November 23, 2026, to speak up online—no fees or money changes yet, just a chance to weigh in!
Previous / Next Documents
Previous: 2026-12645, Rescission of Affirmative Outreach Requirements for Recipients of WIOA Title I Financial Assistance
Starting July 24, 2026, organizations that get money from the Workforce Innovation and Opportunity Act (WIOA) won’t have to follow the old rules about affirmative outreach. This means they no longer must actively reach out to certain groups to promote their programs. The change simplifies things for recipients without affecting funding amounts.
Next: 2026-12654, Schedules of Controlled Substances: Temporary Placement of O-Desmethyltramadol in Schedule I
Starting July 24, 2026, O-desmethyltramadol (also called O-DSMT) will be temporarily placed in Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just possesses it, bringing strict rules and penalties. The move aims to keep people safe while the government studies the drug more closely.